The CHARIOT:Pro Substudy: The Cognitive Health in Ageing Register: Investigational, Observational & Trial Studies in Dementia Research. Royal Infirmary of Edinburgh, NHS Lothian
Through research it has been found that there are clinical changes in the brains of patients diagnosed with Alzheimer's disease (AD) many years before the onset of the disease. It is during the first early symptoms stage and before the signs of 'Mild Cognitive Impairment' (MCI) are apparent that drug intervention may be most successful.
The purpose of this study is to investigate the cognitive and functional changes in patients at risk of developing MCI due to Alzheimer's disease. Participants in this study will have no personal history or diagnosis of Dementia and are deemed low, medium and high risk for developing MCI. Samples of blood, urine and saliva samples will be taken periodically for over 2 years to study different biomarkers that can be risk factors for Dementia or Alzheimer's Disease.
If you would like to read more about this study then please click here.
The Sirukumab Study: A Double-Blind, Placebo-Controlled, Multicentre Study of Sirukumab as Adjunctive Treatment to a MonoAminergic in Adults with Major Depressive Disorder. Royal Edinburgh Hospital.
Mental health problems are one of the main causes of the overall disease burden worldwide. Major Depressive Disorder (MDD) is a significant medical condition that is thought to be the second leading cause of disability and left untreated can lead to a sense of hopelessness and thoughts of self-harm or suicide. MDD impacts both mood and behaviour and can affect many physical functions such as appetite, sleep and concentration. People that suffer from MDD often lose interest in activities they once enjoyed and have trouble performing everyday activities.
This study wants to find out whether a drug called sirukumab is beneficial as an additional treatment in patients diagnosed with MDD where standard oral anti-depressant treatment has been ineffective. Sirukumab has been used previously to treat rheumatoid arthritis and resaerch has suggested that it may also have a beneficial impact on depression and cardiovascular disease.
The CatCh-Cog Study: Capturing Changes in Cognition, Developing a Measure for Progression in Dementia.
In a memory clinic, a neuropsychological assessment is often carried out. This assessment consists of several tasks that evaluates a person's cognition functions, for example, memory, attention, language and planning skills. These tests are not only neccessary for establishing problens in cognitive functioning, but aslo to monitor improvemnet ior decline in cognitive problems. However the neuropsychological assessment that is currently in use can take up to severral hours to complete and can be burdensome to patients. Research also suggests that these tests could be improved upon to better reflect everyday functioning and monitor clinically relevant change over time.
This study aims to develop a new, short measure that is able to detect changes in cognition and everyday functioning. This new measure will consist of neuropsychological test and a questionnaire.
The Eye Tracking Study: An Eye Tracking System for Visual Field Assessments in Children and Adults.
This study wants to test a new system that has been designed to replace current methods of assessing peripheral vision in both adults and children. The new system uses a technique called eye tracking which can monitor exactly where a person is looking at, at any given time. The system that is currently in use requires patients to have a good understanding of the test which can be difficult for any patients that may have learning difficulties or language barriers. The other problem is that to administer the test currently, requires the patients to be in a fixed position throughout and have their head and chin against a rest. This study is looking to recruit healthy volunteers that have no problems with their eyes and visual field to form a control group and compare the old and new systems for eye tracking.
The DexFEM Study: Developmental Clinical Studies - Reversing Endometrial Glucocorticoid Deficiency in Heavy Menstrual Bleeding. Royal Infirmary of Edinburgh, NHS Lothian.
Heavy Menstrual Bleeding (HMB) is a problem that can have a huge impact on a woman's everyday life. Currently there are a number of treatments available but these are often ineffective and cause unacceptable side effects. This has highlighted a need for new medicines that can offer a wider range of effective treatments.
New research has identified a medication that may help reduce the heaviness of periods in women suffering from HMB. The purpose of the DexFEM study is to investigate whether a medication called Dexamethasone would be effective in treating HMB. Dexamethasone has been on the market for a number of years and is normally used to treat many different inflammatory conditions such as allergic disorders, skin conditions, arthritis and lupus to name a few.
This study is now active and recruiting for participants. To hear about any research studies that are relevant to you then all you need to do is register for SHARE today.